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Increasing evidence suggests that neurodevelopmental outcomes after preterm birth are influenced by both genetic and environmental factors. Exposure to magnesium sulfate (MgSO 4 ) before anticipated early preterm birth has been shown to reduce the risk of gross motor dysfunction and cerebral palsy (CP) in surviving children in several clinical trials and in meta-analyses.
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Although the neuroprotective role of MgSO 4 is well established, the mechanism of fetal neuroprotection remains uncertain. MgSO 4 may work via one or more mechanisms including (1) promotion of vascular stability, (2) prevention of hypoxic-ischemic reperfusion injury, (3) reduction in excitatory amino acid damage by acting as a noncompetitive N-methyl-D-aspartic acid receptor antagonist, and/or (4) mitigation of cytokine-mediated inflammatory injury.
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Intrauterine inflammation and the fetal inflammatory response syndrome have been associated with preterm birth, cerebral white-matter damage (periventricular leukomalacia), and CP. [8] [9] [10] [11] [12] A protective mechanism involving mitigation of cytokine-mediated injury, either directly or indirectly, is therefore particularly intriguing. In exploratory studies, fetal gene polymorphisms in inflammation, coagulation, and vascular regulation pathways have been associated with adverse neurodevelopmental outcomes after preterm birth, including CP and neurodevelopmental delay. [13] [14] [15] [16] [17] [18] [19] We sought to confirm these previous observations and also hypothesized that MgSO 4 may influence these genotype associations in a unique geneenvironment interaction. Our objective was to evaluate the associations between candidate gene polymorphisms and MgSO 4 exposure with adverse outcomes, including death, CP, and neurodevelopmental delay, in a cohort of early preterm births.
Materials and Methods

Subjects
Children enrolled in the Eunice Kennedy Shriver National Institute of Child Health and Human Development MaternalFetal Medicine Units Network randomized, placebo-controlled, double-masked multicenter clinical trial of MgSO 4 for the prevention of CP before anticipated preterm birth were studied. Women with singleton or twin gestations between 24 0/7 and 31 6/7 weeks' gestation and at risk of imminent preterm delivery were eligible for enrollment. The primary outcome was a composite of stillbirth or infant death by 1 year of life, and moderate or severe CP at or beyond 2 years of age. Neurodevelopmental delay was included as a secondary outcome, assessed using the Bayley Scales of Infant Development II administered at 2 years of age. The details of the trial, which was conducted between 1997 and 2004, have been previously reported.
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Our nested case-control analysis aimed to evaluate the association of MgSO 4 exposure and candidate gene polymorphisms with death and abnormal neurodevelopment by age 2 years following preterm birth. Inclusion criteria were (1) enrollment in the original MgSO 4 randomized controlled trial, (2) neurological outcome data at age 2 in survivors, and (3) available deoxyribonucleic acid (DNA) for genotyping. Cases either died by 1 year of life or were survivors with abnormal neurodevelopment, defined by CP or neurodevelopmental delay. Neurodevelopmental delay was defined by a score of < 70 (equivalent to 2 standard deviations below the mean) on the Bayley Scales of Infant Development II in either the mental or psychomotor developmental indices (MDI and PDI, respectively), which were administered by centrally certified psychologists or psychometrists. CP was assessed by centrally certified pediatricians or pediatric neurologists according to prespecified criteria (gross motor delay, and abnormality in muscle tone, movement, and reflexes).
1 Controls survived with normal neurodevelopment, defined as Bayley MDI and PDI ! 85 and no diagnosis of grade III/IV intraventricular hemorrhage, periventricular leukomalacia, or CP. The study group for this analysis is illustrated in ►Fig. 1. In the primary study, 2,241 women (2,444 fetuses) participated. We excluded fetal deaths and infants with major congenital malformations. We also excluded children lost to follow-up and children with no available DNA sample. Randomly selected control-group children were matched to case-group children for self-reported maternal race/ethnicity and child sex to minimize the chance of misidentifying a race-based or sex-based genotype association. We excluded samples that either failed to genotype and or had >30% of genotypes missing, and then excluded the corresponding case or control group subjects, to maintain the matching design and ensure valid and accurate genotyping results. One twin from each pair was randomly excluded to avoid the issue of including related individuals in the analysis. This resulted in 406 subjects, 211 cases and 195 controls.
Selection of Polymorphisms for Genotyping
We used a candidate gene approach to evaluate 45 polymorphisms in 19 candidate genes within inflammation, coagulation, and vascular regulation pathways (►Table 1). Polymorphisms were selected based on previously described associations with CP and/or neurodevelopmental delay or involvement in hypothesized causal pathways.
the minor allele was associated with an increased risk of psychomotor delay (adjusted odds ratio 3.3; 95% confidence interval, 1.7-6.5; p < 0.001). Conclusion Candidate gene polymorphisms are associated with death and adverse neurodevelopmental outcomes following preterm birth. MgSO 4 may abrogate this genotype association for some loci.
DNA Extraction, Amplification, and Genotyping DNA was extracted from fetal cord serum using the PureGene DNA Purification System (Qiagen) per the manufacturer's protocols. To increase the available DNA for testing, whole-genome amplification was completed on each sample using the GenomePlex Whole Genome Amplification Kit (Sigma-Aldrich). Genotyping of single nucleotide polymorphisms (SNPs) was accomplished using TaqMan assays (Applied Biosystems). Genotyping for the 1L1RN variable number tandem repeat polymorphism was performed using a fluorescently labeled primer during PCR followed by size determination by capillary electrophoresis against an internal size standard on a 3130xL Genetic Analyzer (Applied Biosystems).
Statistics
Demographic and clinical characteristics of cases and controls were compared using the Chi-square or Fisher's exact test for categorical variables and the Wilcoxon rank-sum test for continuous variables.
Separate analyses compared the association of candidate gene polymorphisms with (1) CP, (2) the combined outcome of CP/death, (3) psychomotor delay, and (4) mental delay.
Death and CP were analyzed as a combined outcome, as was done in the primary randomized clinical trial, since death and CP are competing outcomes.
1 Because this secondary analysis was performed as part of the MgSO 4 trial, in which the treatment affected the risk of adverse neurodevelopmental outcomes, analyses first determined if MgSO 4 modified the relationship between each polymorphism and the adverse neurodevelopmental outcomes described above (treatment interaction). If this treatment interaction was not present, then polymorphisms were analyzed for cases and controls with both treatment groups combined. If this interaction was present, polymorphisms were analyzed according to treatment group. Conditional logistic regression analysis, stratified by maternal race/ethnicity and child sex, was used to account for the matching of cases with controls. Additionally, covariates known a priori to be associated with neurodevelopmental outcomes following preterm birth (gestational age at birth, maternal education level) were included in the models. Initial analyses assumed an additive genetic model, in which each copy of the minor allele confers additional risk. Significant genetic associations were further explored using dominant and recessive genetic models. Exact tests for Hardy-Weinberg equilibrium were performed on control subjects for each polymorphism. 20 As this was an exploratory study, no adjustments were made for multiple comparisons and all comparisons are reported. A p value <0.05 was considered to be statistically significant.
All calculations were performed using SAS software version 9.3 (SAS Institute, Inc., Cary, NC). The institutional review boards (IRB) of the data coordinating center and the clinical sites where subjects were recruited approved the primary data collection. After review by the University of Utah IRB, this secondary analysis was determined to be exempt from IRB approval procedures secondary to deidentification of data and study samples prior to analysis.
Results
Four hundred and six subjects, 211 cases and 195 controls, were analyzed. Among the cases, there were 44 infant deaths, 25 children with CP, 95 children with psychomotor delay, and 113 children with mental delay. Some children had more than one outcome and were included in more than one analysis. Children identified from the parent cohort who satisfied the case inclusion criteria, but had no available DNA, were previously compared with the children with DNA samples available for analysis. 21 Children with DNA available for analysis were more likely to be born at a later gestational age and more likely to be singleton. The demographic and clinical characteristics of study subjects are shown in ►Table 2. Cases delivered significantly earlier than controls, with a mean gestational age of 29.3 versus 30.9 weeks (p < 0.001). The majority of preterm births among cases and controls occurred following preterm premature rupture of membranes. Cases and controls were similar with regard to sex distribution, exposure to antenatal steroids and MgSO 4 , chorioamnionitis, and maternal race/ ethnicity. Maternal education was significantly less in cases versus controls (p < 0.001). Both maternal education and gestational age at delivery were included as covariates in the logistic regression analyses.
In the control group, each polymorphism was in HardyWeinberg equilibrium, with the exception of IL6 SNP rs1800871 (p < 0.001) which was subsequently excluded from analysis. Significant genotype results (p < 0.05), stratified by outcome, are presented in ►Table 3. For SNPs with evidence of MgSO 4 treatment interaction, results are stratified by outcome and treatment group and presented in ►Table 4.
Psychomotor Delay Analyses
One hundred and ninety subjects, 95 cases and 95 controls, were analyzed for the psychomotor delay outcome. Four SNPs in the interleukin 6 receptor (IL6R), one SNP in mannose-binding lectin 2 (MBL2), and one SNP in plasminogen activator inhibitor 1 (PAI1) were associated with psychomotor delay (►Table 3). There was no evidence of MgSO 4 treatment interaction at these loci. The strongest association with psychomotor delay was for a SNP in IL6R (rs 4601580) where each additional copy of the minor allele, T, was associated with an increased risk of psychomotor delay with an odds ratio (OR) of 3.3 (95% confidence interval (CI), 1.7-6.5) using an additive model.
Mental Delay Analyses
Two hundred and twenty-six subjects, 113 cases and 113 controls, were analyzed for the mental delay outcome. Three SNPs in IL6R were associated with mental developmental delay without evidence of MgSO 4 treatment interaction (►Table 3). For example, for rs6687726, the minor allele, A, was associated with mental delay with an OR of 2.5 (95% CI, 1.1-5.4) using a dominant genetic model. Additional SNPs in interleukin 6 (IL6), MBL2, and factor VII (F7) showed evidence of MgSO 4 treatment interaction (►Table 4). The minor allele at the IL6 locus (rs1554606) was associated with reduced risk of mental delay in the magnesium treatment group (OR 0.3; 95% CI, 0.1-0.7); a genotype association was not observed in the placebo group (OR 1.0; 95% CI, 0.6-1.8).
Cerebral Palsy Analyses
One hundred and twenty-five subjects, 25 cases and 100 controls, were analyzed for CP. One SNP in toll-like receptor 4 (TLR4) was associated with CP with an OR of 5.5 (95% CI, 1.1-26.9) for each copy of the minor allele (►Table 3). SNPs in interleukin 1 β (IL1β) and PAI1 showed evidence of MgSO 4 treatment interaction. Minor alleles at these loci were associated with increased risk of CP in the placebo group; exposure to MgSO 4 appeared to abrogate these genotype associations.
Death or Cerebral Palsy Analyses
Two SNPs, one in F7 and one in nitric oxide synthase 3 (NOS3), were associated with the combined outcome of death or CP (►Table 3). There was no evidence of MgSO 4 treatment interaction for this outcome.
Discussion
We used a candidate gene approach to investigate the role of genetic variation and MgSO 4 in neurodevelopment after preterm birth. In the parent trial, treatment with MgSO 4 in women at imminent risk of delivery between 24 and 31 weeks of gestation resulted in a significant decrease in the risk of moderate-to-severe CP in surviving children. Our nested case-control analysis suggests that genetic variants within inflammation, coagulation, and vascular regulation genes may modify neurodevelopmental outcomes after preterm birth. In addition, treatment with MgSO 4 appears to modify these genotype associations at loci within IL6, MBL2, F7, IL1β, and PAI1 genes. These results may help to identify genetic targets for strategies aimed at improving neurodevelopmental outcomes after preterm birth and may also help us to understand the neuroprotective effect of MgSO 4 .
Polymorphisms Related to Inflammation
In this analysis, polymorphisms in the inflammatory cytokine gene IL6 and its receptor (IL6R) were associated with both psychomotor and mental delay. IL6 polymorphisms have previously been associated with impaired cognitive and motor development following preterm birth.
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Genetic variation within IL6 has also been linked to CP in children born at term and near-term. 16 
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outcomes. Amniotic fluid levels of IL6 are influenced by both IL6 and IL6R polymorphisms and there is evidence to suggest that the IL6R genotype may be more important. 24 Our most significant finding is an increased risk of psychomotor delay associated with carriage of an IL6R polymorphism (rs4601580). The functional consequence of this IL6R polymorphism is unknown. The potential contribution of genetic variation in the IL6R to neurodevelopmental outcomes after preterm birth deserves further attention. Polymorphisms in MBL2 gene that result in reduced levels of circulating MBL were associated with reduced risk of psychomotor delay and showed evidence of magnesium treatment interaction for mental delay in this study. MBL plays a role in innate immunity, including activation of the complement cascade. MBL gene polymorphisms have previously been associated with increased risk of CP in children born preterm after perinatal viral exposure 25 and with adverse neurological outcomes in a small population of children born at or before 32 weeks' gestation. 26 These studies suggest that decreased serum MBL levels may be associated with increased risk of adverse neurodevelopmental outcome after preterm birth, possibly due to increased risk of infection-mediated injury. Conversely, adult literature and animal models suggest that loss-of-function MBL gene polymorphisms may be associated with improved outcomes in ischemia reperfusion brain injury (e.g., traumatic brain injury and acute stroke). [27] [28] [29] While MBL gene polymorphisms have been associated with neurologic outcomes in adult and pediatric populations, the relative neuroprotective or harmful characteristics of MBL remain to be elucidated. MBL may have both neuroprotective and injurious properties, depending on clinical circumstances. A polymorphism in the TLR4 gene was associated with increased risk of CP in this analysis. TLR4 is an antigen-binding receptor important in the activation of the innate immune system. Several studies have associated the rs4986790 polymorphism with reduced host immune response in the presence of Gram-negative bacterial infections. 30, 31 This polymorphism has been associated reduced risk of CP in a prior analysis of a mixed gestational age cohort.
32
A polymorphism in the cytokine IL1β gene showed evidence of magnesium treatment interaction for the outcome of CP in this analysis. Previous studies have reported the association between genetic variation in the IL1β gene with CP and adverse neurodevelopmental outcomes.
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Polymorphisms Related to Thrombosis or Thrombolysis PAI1 gene polymorphisms were associated with reduced risk of psychomotor delay and showed evidence of magnesium 
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A F7 polymorphism was associated with the combined outcome of CP/death and showed evidence of magnesium treatment interaction for the mental delay outcome. Genetic variation in the F7 gene has been associated with CP in a previous study of children born very prematurely.
15
Polymorphisms Related to Vascular Regulation
An endothelial NOS3 gene polymorphism was associated a reduced risk of the combined outcome of CP or death in this analysis. Nitric oxide synthases are a family of enzymes catalyzing the production of nitric oxide, which is an important cellular signaling molecule that modulates vascular tone and is involved in angiogenesis and neural development, among other roles. Polymorphisms in endothelial NOS have been previously associated with CP. 15 Polymorphisms of the inducible isoform, which is involved in the immune response, have also been associated with risk of CP in preterm children in previous analyses.
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The strengths of this study include the evaluation of a large cohort of preterm children with appropriate controls and well-characterized obstetrical and neurodevelopmental outcomes. However, neurodevelopmental testing at age 2 may be of limited predictive value for longer-term outcomes. Whether the genetic polymorphisms we report have any longer-term neurocognitive associations of clinical significance is uncertain, and cannot be extrapolated from this data. In addition, our results may not be generalizable to other preterm birth populations and our findings need to be validated in other cohorts.
We acknowledge that some of the observed associations between genotype and neurodevelopmental delay may be due to chance as multiple analyses increase the likelihood of identifying chance statistical associations. However, previous studies have demonstrated associations between inflammation, coagulation, and vascular regulation gene variants and fetal/neonatal central nervous system injury. These studies lend support and biologic plausibility to our findings. To evaluate the possible effect of multiple comparisons, we applied the Holm-Bonferroni method post hoc, where a p value of < 1.3 Â 10 À3 would be considered to be statistically significant. 35 Applying this correction, the SNP in IL6R (rs 4601580) that was associated with an increased risk of psychomotor delay (OR 3.3; 95% CI, 1.7-6.5) remained statistically significant at p < 0.001, withstanding the possible effect of multiple comparisons. No other SNPs met this threshold. In this exploratory analysis, reporting and discussing all associations with a p value <0.05 are important to inform selection of polymorphisms for evaluation and validation in other cohorts. Genes or SNPs in linkage disequilibrium with those we have identified, rather than the genes and SNPs that we report, may be the actual causative variants associated with neurodevelopmental outcomes. In addition, missing genotyping data and sample size, particularly for the CP analysis, may result in true genotype-phenotype associations being missed. Further studies in other populations are needed to confirm or refute the genetic associations described. The sample size and lack of placental pathology also prohibited analysis of the interaction of genotype with maternal/intrauterine infection and neonatal sepsis, gene-environment interactions of obvious interest.
Multiple polymorphisms in IL6 and IL6R were selected based on previously described associations with neurodevelopmental outcomes and involvement in hypothesized causal pathways. The candidate SNPs selected for this analysis do not fully capture the genetic variation within each gene. Formal haplotype analyses of these genes, via inclusion of additional loci, should be the focus of future studies.
The risk of central nervous system injury in preterm children is influenced by complex gene-environment interactions that are not well understood. This study supports the hypothesis that gene variants may influence the risk of death and adverse neurodevelopmental outcomes after preterm birth, and may also influence the response to MgSO 4 neuroprophylaxis. Ultimately, a better understanding of genetic factors that predispose to these outcomes may lend mechanistic insight and may inform future clinical trials focused on prevention and treatment.
